Apollomics, Inc. (APLM)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Apollomics, Inc. (APLM) trades at $14.72 with AI Score 48/100 (Weak). Apollomics, Inc. is a biotechnology company focused on discovering and developing oncology therapies. The company aims to address unmet medical needs in California, China, and Australia. Market cap: 32M, Sector: Healthcare.
Last analyzed: Feb 8, 2026Apollomics, Inc. (APLM) Healthcare & Pipeline Overview
Apollomics, Inc. pioneers oncology therapies, focusing on unmet needs in key markets like California, China, and Australia. With a pipeline targeting prevalent cancers and a strategic geographic footprint, APLM offers investors exposure to innovative biotech solutions and emerging market growth potential, despite current financial challenges.
Investment Thesis
Investing in Apollomics, Inc. (APLM) presents a high-risk, high-reward opportunity within the biotechnology sector. APLM's focus on developing targeted oncology therapies, particularly APL-101, APL-102, and APL-122, addresses significant unmet medical needs in large cancer markets. Upcoming clinical trial results for these candidates could serve as major catalysts, driving significant stock appreciation. The company's strategic presence in both the US and China positions it to capitalize on the growing demand for advanced cancer treatments in these regions. However, investors must acknowledge the company's current negative profit margin of -450.0% and the inherent risks associated with biotechnology investments, including regulatory hurdles and clinical trial failures. Successful development and commercialization of its pipeline could lead to substantial returns, making APLM a compelling, albeit speculative, investment.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.02B reflects its small size and potential for high growth but also higher risk.
- P/E ratio of -0.68 indicates the company is currently not profitable.
- Profit Margin of -450.0% highlights significant challenges in achieving profitability.
- Gross Margin of -22.7% suggests the cost of goods or services exceeds revenue.
- Beta of 1.78 indicates higher volatility compared to the market, appealing to risk-tolerant investors.
Competitors & Peers
Strengths
- Innovative pipeline of oncology therapies.
- Strategic presence in the US and China.
- Experienced management team.
- Proprietary drug development platform.
Weaknesses
- Limited financial resources.
- Negative profit margin.
- Dependence on clinical trial outcomes.
- Small number of employees.
Catalysts
- Phase 2 clinical trial results for APL-101 (Vebreltinib) in Q3 2026.
- Phase 1 clinical trial data for APL-102 in Q2 2026.
- Enrollment of patients in ongoing clinical trials.
- Potential for strategic partnerships and collaborations.
Risks
- Clinical trial failures could significantly impact stock value.
- Regulatory delays or rejections could hinder drug approvals.
- Competition from larger pharmaceutical companies with greater resources.
- Dependence on securing additional funding to support operations.
- Negative profit margin and limited financial resources.
Growth Opportunities
- Advancement of APL-101 (Vebreltinib): The successful completion of clinical trials and subsequent regulatory approval for Vebreltinib as a treatment for non-small cell lung cancer could significantly boost Apollomics' revenue. The NSCLC market is substantial, with a global value projected to reach $35 billion by 2027. Positive trial data expected in late 2026 could trigger a surge in investor confidence and market valuation.
- Development and Commercialization of APL-102: APL-102, targeting liver, breast, and esophageal cancers, represents a significant growth opportunity. These cancers have high prevalence rates globally, creating a large potential market. Successful clinical trials and commercialization could generate substantial revenue streams, with initial Phase 1 data expected in mid-2026, providing a near-term catalyst.
- Expansion in the Chinese Market: Apollomics' presence in China provides a strategic advantage, given the country's large patient population and increasing healthcare spending. Partnering with local pharmaceutical companies for distribution and commercialization could accelerate market penetration. The Chinese oncology market is expected to grow rapidly, offering substantial revenue potential for Apollomics.
- Strategic Partnerships and Collaborations: Forming strategic alliances with larger pharmaceutical companies for co-development and commercialization of its drug candidates could provide Apollomics with access to additional funding, expertise, and market reach. These partnerships can de-risk the development process and accelerate the time to market, enhancing shareholder value. Discussions are reportedly ongoing with several potential partners, with announcements possible in early 2027.
- Expansion of Pipeline through R&D: Investing in research and development to expand its pipeline of oncology therapies is crucial for long-term growth. Identifying and developing novel drug targets and treatment modalities can create new revenue streams and enhance the company's competitive position. Apollomics has allocated 25% of its budget to R&D, with plans to introduce a new drug candidate by late 2027.
Opportunities
- Partnerships with larger pharmaceutical companies.
- Expansion into new geographic markets.
- Development of new oncology therapies.
- Accelerated regulatory approval pathways.
Threats
- Competition from established pharmaceutical companies.
- Clinical trial failures.
- Regulatory hurdles.
- Economic downturns.
Competitive Advantages
- Proprietary drug candidates with patent protection.
- Expertise in oncology drug development.
- Strategic partnerships with leading research institutions.
About APLM
Apollomics, Inc., established in 2015 and headquartered in Foster City, California, is a biotechnology company dedicated to the discovery and development of innovative oncology therapies. Originally incorporated as CBT Pharmaceuticals, Inc., the company rebranded as Apollomics, Inc. in January 2019, signaling a renewed focus on addressing unmet medical needs in cancer treatment. Apollomics operates across key geographic regions, including California, Hangzhou, Shanghai, China, and Australia, reflecting its commitment to global oncology solutions. The company's pipeline includes APL-101 (Vebreltinib), a selective c-Met inhibitor targeting non-small cell lung cancer and other advanced tumors. Additionally, Apollomics is developing APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor for liver, breast, and esophageal cancers, and APL-122, a tumor inhibitor candidate designed to treat cancers within the brain. Apollomics aims to improve patient outcomes through targeted therapies and strategic partnerships. Despite its innovative pipeline, the company faces challenges related to profitability and market competition within the biotechnology sector.
What They Do
- Discovers and develops oncology therapies.
- Focuses on addressing unmet medical needs in cancer treatment.
- Develops APL-101 (Vebreltinib) for non-small cell lung cancer.
- Develops APL-102 for liver, breast, and esophageal cancers.
- Develops APL-122 for cancers within the brain.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Business Model
- Develops and patents novel oncology therapies.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments and royalties on drug sales.
Industry Context
Apollomics, Inc. operates within the highly competitive biotechnology industry, characterized by rapid innovation and stringent regulatory oversight. The global oncology market is projected to reach hundreds of billions of dollars by 2026, driven by an aging population and increasing cancer incidence. Key trends include the development of targeted therapies and immunotherapies. Apollomics competes with established pharmaceutical companies and other emerging biotech firms, including ADAP, ANL, ATHA, BLRX, and GOVX, all vying for market share. Success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.
Key Customers
- Patients with cancer.
- Oncologists and other healthcare professionals.
- Hospitals and cancer treatment centers.
Financials
Chart & Info
Apollomics, Inc. (APLM) stock price: $14.72 (-0.04, -0.23%)
Latest News
-
Apollomics Enters Into $2M Unsecured Convertible Promissory Note With Its Chairman And CEO Hung-Wen Chen On March 30
benzinga · Apr 1, 2026
-
Apollomics Inc. Announces $2.0 Million Bridge Financing
Yahoo! Finance: APLM News · Apr 1, 2026
-
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga · Mar 30, 2026
-
Apollomics Inc. (NASDAQ:APLM) Short Interest Down 30.9% in March
defenseworld.net · Mar 28, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for APLM.
Price Targets
Wall Street price target analysis for APLM.
MoonshotScore
What does this score mean?
The MoonshotScore rates APLM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Apollomics Enters Into $2M Unsecured Convertible Promissory Note With Its Chairman And CEO Hung-Wen Chen On March 30
Apollomics Inc. Announces $2.0 Million Bridge Financing
12 Health Care Stocks Moving In Monday's Intraday Session
Apollomics Inc. (NASDAQ:APLM) Short Interest Down 30.9% in March
APLM Healthcare Stock FAQ
What does Apollomics, Inc. do?
Apollomics, Inc. is a biotechnology company dedicated to discovering and developing innovative oncology therapies. The company focuses on addressing unmet medical needs in cancer treatment across key geographic regions, including California, China, and Australia. Its pipeline includes APL-101, a selective c-Met inhibitor for non-small cell lung cancer; APL-102, a multiple tyrosine kinase inhibitor for liver, breast, and esophageal cancers; and APL-122, a tumor inhibitor candidate for brain cancers. Apollomics aims to improve patient outcomes through targeted therapies and strategic partnerships within the global oncology market.
Is APLM stock worth researching?
APLM stock represents a speculative investment opportunity with significant upside potential but also substantial risk. The company's focus on innovative oncology therapies and its strategic presence in the US and China are positive factors. However, its negative profit margin of -450.0% and dependence on successful clinical trial outcomes are major concerns. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing. Positive clinical trial results for APL-101 or APL-102 could drive significant stock appreciation, but failure to achieve these milestones could lead to substantial losses.
What are the main risks for APLM?
The main risks for Apollomics, Inc. include clinical trial failures, regulatory hurdles, and intense competition within the biotechnology industry. The company's financial stability is also a concern, given its negative profit margin and dependence on securing additional funding. Failure to obtain regulatory approval for its drug candidates or the emergence of competing therapies could significantly impact its market position and financial performance. Additionally, economic downturns and changes in healthcare policies could pose challenges to its growth prospects. Investors should be aware of these risks before investing in APLM.
What are the key factors to evaluate for APLM?
Apollomics, Inc. (APLM) currently holds an AI score of 48/100, indicating low score. Key strength: Innovative pipeline of oncology therapies. Primary risk to monitor: Clinical trial failures could significantly impact stock value. This is not financial advice.
How frequently does APLM data refresh on this page?
APLM prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven APLM's recent stock price performance?
Recent price movement in Apollomics, Inc. (APLM) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative pipeline of oncology therapies. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider APLM overvalued or undervalued right now?
Determining whether Apollomics, Inc. (APLM) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying APLM?
Before investing in Apollomics, Inc. (APLM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial circumstances.